R-Pharm has filed an innovative COVID-19 medicine patent application

March 30

March 30, 2019 – R-Pharm Group has filed its first international patent application regarding biotech medicine that binds viral particles of COVID-19 and prevents them from penetrating alveolar cells.

“Research and development of this medicine is on early stages. Despite that, it is very important for us, so we decided to speed it up. We believe, that along with other promising drug candidates, this molecule is on its way to land a decisive strike against COVID-19 both in Russia and around the world”, stated R-Pharm’s chairman of the board Alexey Repik.

Group has launched a set of comprehensive measures aiming to curb COVID-19 pandemic. These measures range from development of new molecules and therapy methods to reevaluation of the current product portfolio.

Other company news

Deltyba® (delamanid) —an essential medicine according to the World Health Organization [1]—is now available in Russia for...
read more...
May 25
Considering COVID-19 pandemic, R-Pharm Group has taken the following measures to achieve better health protection of R-Pharm employees and...
read more...
March 24
On November 12, 2019, a poster presentation of the TOP line results of CREDO 1 clinical study, the first study of a large-scale CREDO...
read more...
November 29